Artikel: Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
Experimental hematology & oncology
2022 Band 11, Heft 1, Seite(n) 54
Abstract: Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy ... to normal B cells. Using the clinically applicable GPER1-selective small-molecule agonist G-1 (also named ... agonist G-1. ...
Abstract | Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated in tumor cells from different cohorts of Waldenström Macroglobulinemia (WM) patients compared to normal B cells. Using the clinically applicable GPER1-selective small-molecule agonist G-1 (also named Tespria), we found that pharmacological activation of GPER1 leads to G2/M cell cycle arrest and apoptosis both in vitro and in vivo in animal models, even in the context of the protective bone marrow milieu. Activation of GPER1 triggered the TP53 pathway, which remains actionable during WM progression. Thus, this study identifies a novel therapeutic target in WM and paves the way for the clinical development of the GPER1 agonist G-1. |
---|---|
Sprache | Englisch |
Erscheinungsdatum | 2022-09-12 |
Erscheinungsland | England |
Dokumenttyp | Letter |
ZDB-ID | 2669066-4 |
ISSN | 2162-3619 |
ISSN | 2162-3619 |
DOI | 10.1186/s40164-022-00305-x |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.